Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Methodological standard · Content

CEI-MS-10 — Identification and quantification of counter-ions in synthetic peptide salts

Identification and quantification of counter-ions in synthetic peptide salts

Document identifier
CEI-MS-10
Series
Methodological standard
Version
1.2
Published
31 May 2024
Last reviewed
31 Jul 2025
Next review
31 Jul 2028
Identifier
10.71829/cei.meth.9
Certainty
High
Cycle
2024 Q2
Category
Content

§1Scope

§1.1Scope

Applies to all synthetic peptides supplied as salts, which in practice means all of them. Establishes that counter-ion identity and content are part of the specification and not a residue to be disregarded.

§2Principle

A peptide with basic residues is isolated from reverse-phase purification as a salt of the mobile-phase acid, most commonly trifluoroacetate or acetate. The counter-ion associates approximately stoichiometrically with each protonatable site, so its mass fraction is determined by the number of basic residues and the peptide’s molecular mass. For small polybasic peptides this fraction is large. An acidic peptide with no basic residues carries a cation rather than an anion, and a trifluoroacetate determination on such a peptide is meaningless.[1,2]

§3Apparatus and reagents

§3.1Apparatus

  • Ion chromatograph with suppressed conductivity detection for anions
  • Capillary electrophoresis as an alternative for trifluoroacetate
  • ¹⁹F nuclear magnetic resonance spectrometer as an orthogonal method for trifluoroacetate
  • Ion chromatograph with cation-exchange column for sodium and ammonium

§3.2Reagents and reference materials

  • Anion-exchange eluent, typically carbonate or hydroxide gradient
  • Trifluoroacetate and acetate standards
  • Cation standards for sodium, potassium and ammonium
  • A fluorine-containing internal standard for the NMR method

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. United States Pharmacopeial Convention. General Chapter ⟨1225⟩ Validation of Compendial Procedures. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
  2. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q2(R2) Validation of Analytical Procedures. ICH Harmonised Guideline 2023;Step 4 version, 1 November 2023. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.